|
| 36525618 | Long-Term Morbidity and Mortality Among Survivors of Neuroblastoma Diagnosed During Infancy: A Report From the Childhood Cancer Survivor Study. | J Clin Oncol | 2023 |
| 37693610 | Adrenergic and mesenchymal signatures are identifiable in cell-free DNA and correlate with metastatic disease burden in children with neuroblastoma. | | 2023 |
| 37425883 | T-cell inflammation is prognostic of survival in patients with high-risk neuroblastoma enriched for an adrenergic signature. | bioRxiv | 2023 |
| 37098238 | Survival of Patients With Neuroblastoma After Assignment to Reduced Therapy Because of the 12- to 18-Month Change in Age Cutoff in Children's Oncology Group Risk Stratification. | J Clin Oncol | 2023 |
| 36720647 | Multimodality treatment for recurrent neuroblastoma in the central nervous system. | | 2023 |
| 35665495 | Efficacy of post-induction therapy for high-risk neuroblastoma patients with end-induction residual disease. | Cancer | 2022 |
| 35839426 | Outcomes Following GD2-Directed Postconsolidation Therapy for Neuroblastoma After Cessation of Random Assignment on ANBL0032: A Report From the Children's Oncology Group. | J Clin Oncol | 2022 |
| 35441788 | Rethinking high-risk neuroblastoma treatment. | Pediatric Blood and Cancer | 2022 |
| 35942521 | MYCN and HIF-1 directly regulate <i>TET1</i> expression to control 5-hmC gains and enhance neuroblastoma cell migration in hypoxia. | Epigenetics | 2022 |
| 36129889 | The Experience of Children With Neuroblastoma and Their Parents During Single-Room Isolation for I-Metaiodobenzylguanidine Therapy: A Qualitative Descriptive Study. | Journal of Pediatric Hematology/Oncology Nursing | 2022 |
| 34882497 | Predicting Response to Chemotherapy in Patients With Newly Diagnosed High-Risk Neuroblastoma: A Report From the International Neuroblastoma Risk Group. | JCO Clin Cancer Inform | 2021 |
| 34236408 | Association Between Participation in Clinical Trials and Overall Survival Among Children With Intermediate- or High-risk Neuroblastoma. | JAMA Netw Open | 2021 |
| 33739795 | Stage 4S Neuroblastoma: Molecular, Histologic, and Immunohistochemical Characteristics and Presence of 2 Distinct Patterns of MYCN Protein Overexpression-A Report From the Children's Oncology Group. | Am J Surg Pathol | 2021 |
| 34272305 | Immunogenomic determinants of tumor microenvironment correlate with superior survival in high-risk neuroblastoma. | J Immunother Cancer | 2021 |
| 34270348 | Randomized Phase II Trial of MIBG Versus MIBG, Vincristine, and Irinotecan Versus MIBG and Vorinostat for Patients With Relapsed or Refractory Neuroblastoma: A Report From NANT Consortium. | J Clin Oncol | 2021 |
| 33504555 | Long-Term Follow-up of a Phase III Study of ch14.18 (Dinutuximab) + Cytokine Immunotherapy in Children with High-Risk Neuroblastoma: COG Study ANBL0032. | Clin Cancer Res | 2021 |
| 34319759 | Revised Neuroblastoma Risk Classification System: A Report From the Children's Oncology Group. | J Clin Oncol | 2021 |
| 33205902 | A nomogram of clinical and biologic factors to predict survival in children newly diagnosed with high-risk neuroblastoma: An International Neuroblastoma Risk Group project. | Pediatr Blood Cancer | 2021 |
| 34662145 | Pediatric Cancer Data Commons: Federating and Democratizing Data for Childhood Cancer Research. | JCO Clin Cancer Inform | 2021 |
| 33058692 | Tailoring Therapy for Children With Neuroblastoma on the Basis of Risk Group Classification: Past, Present, and Future. | JCO Clin Cancer Inform | 2020 |
| 31852832 | 5-Hydroxymethylcytosine Profiles in Circulating Cell-Free DNA Associate with Disease Burden in Children with Neuroblastoma. | Clin Cancer Res | 2020 |
| 32315273 | Age, Diagnostic Category, Tumor Grade, and Mitosis-Karyorrhexis Index Are Independently Prognostic in Neuroblastoma: An INRG Project. | J Clin Oncol | 2020 |
| 32360991 | Racial and Ethnic Differences in Communication and Care for Children With Advanced Cancer. | Journal of Pain and Symptom Management | 2020 |
| 31812554 | Pembrolizumab in paediatric patients with advanced melanoma or a PD-L1-positive, advanced, relapsed, or refractory solid tumour or lymphoma (KEYNOTE-051): interim analysis of an open-label, single-arm, phase 1-2 trial. | Lancet Oncol | 2020 |
| 32472953 | Paraneoplastic opsoclonus myoclonus syndrome associated with inflammatory myofibroblastic tumor in a pediatric patient. | Pediatric Blood and Cancer | 2020 |
| 32472746 | The prognostic strength of serum LDH and serum ferritin in children with neuroblastoma: A report from the International Neuroblastoma Risk Group (INRG) project. | Pediatr Blood Cancer | 2020 |
| 32710697 | Association between end-induction response according to the revised International Neuroblastoma Response Criteria (INRC) and outcome in high-risk neuroblastoma patients. | Pediatric Blood and Cancer | 2020 |
| 32931402 | Reply to K. Beiske et al. | J Clin Oncol | 2020 |
| 32903140 | Age Dependency of the Prognostic Impact of Tumor Genomics in Localized Resectable <i>MYCN</i>-Nonamplified Neuroblastomas. Report From the SIOPEN Biology Group on the LNESG Trials and a COG Validation Group. | J Clin Oncol | 2020 |
| 30674566 | Maternal Embryonic Leucine Zipper Kinase (MELK), a Potential Therapeutic Target for Neuroblastoma. | Molecular Cancer Therapeutics | 2019 |
| 30444686 | Defining Risk Factors for Chemotherapeutic Intervention in Infants With Stage 4S Neuroblastoma: A Report From Children's Oncology Group Study ANBL0531. | J Clin Oncol | 2019 |
| 30479064 | The challenge of defining "ultra-high-risk" neuroblastoma. | Pediatr Blood Cancer | 2019 |
| 31179414 | 5-Hydroxymethylcytosine Profiles Are Prognostic of Outcome in Neuroblastoma and Reveal Transcriptional Networks That Correlate With Tumor Phenotype. | JCO Precis Oncol | 2019 |
| 31454045 | Effect of Tandem Autologous Stem Cell Transplant vs Single Transplant on Event-Free Survival in Patients With High-Risk Neuroblastoma: A Randomized Clinical Trial. | JAMA | 2019 |
| 30968542 | Role of the extent of prophylactic regional lymph node radiotherapy on survival in high-risk neuroblastoma: A report from the COG A3973 study. | Pediatr Blood Cancer | 2019 |
| 29191664 | Immune Reconstitution Following Autologous Stem Cell Transplantation in Patients with High-Risk Neuroblastoma at the Time of Immunotherapy. | Biology of Blood and Marrow Transplantation | 2018 |
| 28972044 | Neuroblastoma Patients' KIR and KIR-Ligand Genotypes Influence Clinical Outcome for Dinutuximab-based Immunotherapy: A Report from the Children's Oncology Group. | Clin Cancer Res | 2018 |
| 30198643 | Computer-assisted Curie scoring for metaiodobenzylguanidine (MIBG) scans in patients with neuroblastoma. | Pediatr Blood Cancer | 2018 |
| 30093449 | Phase II Trial of Alisertib in Combination with Irinotecan and Temozolomide for Patients with Relapsed or Refractory Neuroblastoma. | Clin Cancer Res | 2018 |
| 30652588 | Statistical Framework in Support of a Revised Children's Oncology Group Neuroblastoma Risk Classification System. | JCO clinical cancer informatics | 2018 |
| 29376112 | Intravenous immunoglobulin with prednisone and risk-adapted chemotherapy for children with opsoclonus myoclonus ataxia syndrome associated with neuroblastoma (ANBL00P3): a randomised, open-label, phase 3 trial. | Lancet Child Adolesc Health | 2018 |
| 28033528 | Neuroblastoma survivors are at increased risk for second malignancies: A report from the International Neuroblastoma Risk Group Project. | Eur J Cancer | 2017 |
| 28864906 | Composite tumor with pheochromocytoma and immature neuroblastoma: report of two cases with cytogenetic analysis and discussion of current terminology. | Virchows Archiv | 2017 |
| 28561664 | Data Commons to Support Pediatric Cancer Research. | Am Soc Clin Oncol Educ Book | 2017 |
| 28471719 | Revisions to the International Neuroblastoma Response Criteria: A Consensus Statement From the National Cancer Institute Clinical Trials Planning Meeting. | J Clin Oncol | 2017 |
| 29464082 | MYC-family protein overexpression and prominent nucleolar formation represent prognostic indicators and potential therapeutic targets for aggressive high-MKI neuroblastomas: a report from the children's oncology group. | Oncotarget | 2017 |
| 29117357 | Evaluation of Genetic Predisposition for MYCN-Amplified Neuroblastoma. | J Natl Cancer Inst | 2017 |
| 29062613 | Emerging and investigational therapies for neuroblastoma. | Expert Opinion on Orphan Drugs | 2017 |
| 27663277 | Rebound thymic hyperplasia following high dose chemotherapy and stem cell transplant in three neuroblastoma patients. | Pediatric Blood and Cancer | 2017 |
| 28061552 | The Role of Nursing Professionals in the Management of Patients With High-Risk Neuroblastoma Receiving Dinutuximab Therapy. | Journal of Pediatric Oncology Nursing | 2017 |